OR WAIT null SECS
January 07, 2021
The company plans to deliver initial doses by mid-2021, and Australia will have the option to purchase up to 10 million additional doses through the agreement.
Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.
January 04, 2021
The companies have entered into an agreement to support the formulation and fill/finish of Moderna’s COVID-19 vaccine supply outside of the United States.
Part of Operation Warp Speed, the trial will enroll 30,000 people ages 18 to 64 and 65 and older at 115 sites.
January 02, 2021
Shutting down the COVID-19 pandemic requires a global, selfless effort.
December 31, 2020
Administration of the COVID-19 vaccination from Oxford University and AstraZeneca is expected to begin in the UK in early 2021.
December 21, 2020
Moderna’s mRNA vaccine to prevent COVID-19 disease is granted FDA Emergency Use Authorization and CDC recommendation.
December 16, 2020
A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.
The company has formed an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s COVID-19 vaccine candidate, to the people of Singapore.
December 15, 2020
The HERALD trial will involve participants 18 years and older who will receive a two-dose schedule of CVnCoV or placebo at multiple sites is Europe and Latin America.